mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28− Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection-Reference-Cited by-同舟云学术

mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28− Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection

Published:2020-05 Issue:5 Volume:104 Page:1058-1069
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:

Author:

Castro-Rojas Cyd M.,Godarova Alzbeta,Shi Tiffany,Hummel Sarah A.,Shields Adele,Tremblay Simon,Alloway Rita R.,Jordan Michael B.,Woodle E. Steve,Hildeman David A.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference32 articles.

1. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.;Larsen;Am J Transplant,2005

2. Does belatacept improve outcomes for kidney transplant recipients? A systematic review.;Talawila;Transpl Int,2015

3. The clearer BENEFITS of belatacept.;Heher;N Engl J Med,2016

4. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).;Vincenti;Am J Transplant,2010

5. Belatacept and long-term outcomes in kidney transplantation.;Vincenti;N Engl J Med,2016

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Entangled World of Memory T Cells and Implications in Transplantation;Transplantation;2023-12-13

2. Single-cell transcriptomic analysis of renal allograft rejection reveals insights into intragraft TCR clonality;Journal of Clinical Investigation;2023-07-17

3. mTOR Inhibition Impairs the Activation and Function of Belatacept-Resistant CD4+CD57+ T Cells In Vivo and In Vitro;Pharmaceutics;2023-04-20

4. Single cell transcriptomic analysis of renal allograft rejection reveals novel insights into intragraft TCR clonality;2023-02-08

5. Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression;Transplantation Direct;2023-01-06